Point72 Asset Management L.P. lessened its position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) by 8.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,456 shares of the company’s stock after selling 600 shares during the period. Point72 Asset Management L.P.’s holdings in Crispr Therapeutics were worth $265,000 at the end of the most recent reporting period.
A number of other large investors have also recently made changes to their positions in CRSP. NEXT Financial Group Inc raised its stake in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock valued at $25,000 after purchasing an additional 549 shares during the period. Benjamin Edwards Inc. boosted its holdings in shares of Crispr Therapeutics by 96.4% during the second quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after acquiring an additional 268 shares during the period. Coastal Investment Advisors Inc. bought a new position in shares of Crispr Therapeutics during the third quarter worth about $26,000. US Bancorp DE increased its holdings in shares of Crispr Therapeutics by 553.7% in the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the period. Finally, BSW Wealth Partners acquired a new position in Crispr Therapeutics during the 2nd quarter valued at about $39,000. Institutional investors own 49.82% of the company’s stock.
Several analysts have weighed in on CRSP shares. Wells Fargo & Co reaffirmed a “buy” rating on shares of Crispr Therapeutics in a research note on Friday, December 6th. William Blair raised shares of Crispr Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, November 19th. Zacks Investment Research lowered Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a report on Monday, October 28th. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $104.00 target price on shares of Crispr Therapeutics in a report on Tuesday, November 26th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and fourteen have issued a buy rating to the company’s stock. Crispr Therapeutics presently has an average rating of “Buy” and a consensus price target of $69.54.
Shares of CRSP stock traded down $0.67 during mid-day trading on Friday, reaching $65.36. The company’s stock had a trading volume of 737,055 shares, compared to its average volume of 1,674,626. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $58.93 and its two-hundred day moving average is $48.44. Crispr Therapeutics AG has a 1-year low of $22.22 and a 1-year high of $74.00.
Crispr Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The firm had revenue of $211.93 million during the quarter, compared to analysts’ expectations of $6.32 million. On average, equities research analysts forecast that Crispr Therapeutics AG will post 0.65 earnings per share for the current fiscal year.
In other news, Director Pablo J. Cagnoni sold 7,500 shares of the firm’s stock in a transaction that occurred on Wednesday, October 30th. The shares were sold at an average price of $52.00, for a total transaction of $390,000.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at approximately $390,000. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the sale, the president now directly owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,118 shares of company stock worth $3,620,760. Insiders own 21.40% of the company’s stock.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Read More: Trading on Margin
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.